Singla Rohin, Sidaras Chelsey, Patel Jignesh K
Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, Stony Brook Renaissance School of Medicine, Stony Brook, NY, USA.
Ther Adv Pulm Crit Care Med. 2025 Jun 4;20:29768675251346014. doi: 10.1177/29768675251346014. eCollection 2025 Jan-Dec.
Inflammatory, neurologic, and cardiac biomarkers appear to have varying significance in the prognostication of patients with cardiac arrest. Post-cardiac arrest syndrome is a condition characterized by systemic ischemia with reperfusion injury, neurologic damage, and myocardial dysfunction. The relative significance of these biomarkers remains unclear and is an area of active investigation. In this narrative review, we aim to describe what is currently known about the role of inflammatory, neurologic, and cardiac biomarkers in cardiac arrest. A PubMed review was performed for relevant articles. Articles that studied inflammatory, neurologic, and cardiac biomarkers in adult cardiac arrest were included. This narrative review determined that biomarkers play a key role in facilitating prognostication of patients with cardiac arrest. The release of inflammatory, neurologic, and cardiac biomarkers mediates inflammation, ischemic brain injury, and myocardial dysfunction. Inflammatory and neurologic biomarkers appear to have more clinical utility than cardiac biomarkers. When combined with physical exam, imaging and electroencephalograph findings, blood biomarkers can be useful in making predictions of patient outcomes post-cardiac arrest. Despite this utility, no single biomarker has sufficient power to predict patient outcomes independently. Ongoing research investigating these biomarkers remains an area of strong clinical interest. In conclusion, inflammatory, neurologic, and cardiac biomarkers all play a role in understanding both the short-term and long-term outcomes in patients with cardiac arrest. To date, no single parameter has been shown to reliably predict outcome in cardiac arrest patients. Such biomarkers remain an area of active investigation.
炎症、神经和心脏生物标志物在心脏骤停患者的预后评估中似乎具有不同的意义。心脏骤停后综合征是一种以全身缺血伴再灌注损伤、神经损伤和心肌功能障碍为特征的病症。这些生物标志物的相对重要性仍不清楚,是一个正在积极研究的领域。在这篇叙述性综述中,我们旨在描述目前已知的炎症、神经和心脏生物标志物在心脏骤停中的作用。我们在PubMed上检索了相关文章。纳入了研究成人心脏骤停中炎症、神经和心脏生物标志物的文章。这篇叙述性综述确定,生物标志物在促进心脏骤停患者的预后评估中起着关键作用。炎症、神经和心脏生物标志物的释放介导炎症、缺血性脑损伤和心肌功能障碍。炎症和神经生物标志物似乎比心脏生物标志物具有更大的临床应用价值。当与体格检查、影像学和脑电图结果相结合时,血液生物标志物可有助于预测心脏骤停后的患者预后。尽管有这种应用价值,但没有单一生物标志物有足够的能力独立预测患者预后。对这些生物标志物的持续研究仍然是一个具有强烈临床兴趣的领域。总之,炎症、神经和心脏生物标志物在理解心脏骤停患者的短期和长期预后方面都发挥着作用。迄今为止,没有单一参数被证明能可靠地预测心脏骤停患者的预后。此类生物标志物仍然是一个积极研究的领域。